Role of Faecal Calprotectin in Patients With Abdominal Pain

Inflammation Clinical Trial

Official title:

Role of Faecal Calprotectin in Patients Presenting to the Emergency Department With Abdominal Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05795985
• Other study ID #: 4183
• Status: Completed
• Start date: July 1, 2021
• Est. completion date: March 1, 2023

Study information

• Verified date: April 2023
• Source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The evaluation of patients with abdominal pain is a challenge for the emergency physician and the selection of patients for second-level radiological examinations or endoscopic procedures is not always easy to perform. Faecal calprotectin could be a useful diagnostic marker to distinguish between "organic" or "functional" form and its determination could be helpful to select patients for further examinations, in the context of emergency setting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 146
• Est. completion date: March 1, 2023
• Est. primary completion date: December 31, 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with abdominal pain and/or diarrhea and/or rectal bleeding

Exclusion Criteria:

• patients with age < 18 years

• pregnant women;

• patients with oncological, cardiological, nephrological terminal diseases;

• patients on antibiotic therapy or who have taken it during the last month;

• patients with a history of colic resection or gastrointestinal surgery;

• patients with a previous diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis)

Related Conditions & MeSH terms

• Abdominal Pain
• Inflammation

Intervention

Diagnostic Test:
• calprotectin levels
dosage of calprotectin levels in patients with abdominal pain

Locations

Country	Name	City	State
Italy	Fondazione Policlinico Universitario A. Gemelli IRCCS	Roma

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	inflammation	assess the degree of intestinal inflammation by fecal calprotectin assay in patients with abdominal pain	3 days